Aurobindo Pharma Dirección

Dirección controles de criterios 3/4

El CEO de Aurobindo Pharma es Kambam Reddy , nombrado en Jun 2006, tiene una permanencia de 18.42 años. compensación anual total es ₹45.05M, compuesta por 50.9% salario y 49.1% primas, incluidas acciones y opciones de la empresa. posee directamente un 5.61% de las acciones de la empresa, por valor de ₹40.28B. La antigüedad media del equipo directivo y de la junta directiva es de 9.5 años y 5.5 años, respectivamente.

Información clave

Kambam Reddy

Chief Executive Officer (CEO)

₹45.0m

Compensación total

Porcentaje del salario del CEO	50.9%
Permanencia del CEO	18.4yrs
Participación del CEO	5.6%
Permanencia media de la dirección	9.5yrs
Promedio de permanencia en la Junta Directiva	5.5yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Kambam Reddy en comparación con los beneficios de Aurobindo Pharma?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	₹36b
Jun 30 2024	n/a	n/a	₹35b
Mar 31 2024	₹45m	₹23m	₹32b
Dec 31 2023	n/a	n/a	₹28b
Sep 30 2023	n/a	n/a	₹23b
Jun 30 2023	n/a	n/a	₹20b
Mar 31 2023	₹37m	₹19m	₹19b
Dec 31 2022	n/a	n/a	₹20b
Sep 30 2022	n/a	n/a	₹21b
Jun 30 2022	n/a	n/a	₹24b
Mar 31 2022	₹27m	₹14m	₹26b
Dec 31 2021	n/a	n/a	₹29b
Sep 30 2021	n/a	n/a	₹52b
Jun 30 2021	n/a	n/a	₹53b
Mar 31 2021	₹23m	₹20m	₹53b
Dec 31 2020	n/a	n/a	₹54b
Sep 30 2020	n/a	n/a	₹31b
Jun 30 2020	n/a	n/a	₹30b
Mar 31 2020	₹15m	₹13m	₹28b
Dec 31 2019	n/a	n/a	₹26b
Sep 30 2019	n/a	n/a	₹26b
Jun 30 2019	n/a	n/a	₹25b
Mar 31 2019	₹15m	₹13m	₹24b
Dec 31 2018	n/a	n/a	₹23b
Sep 30 2018	n/a	n/a	₹22b
Jun 30 2018	n/a	n/a	₹24b
Mar 31 2018	₹15m	₹13m	₹24b

Compensación vs. Mercado: La compensación total de Kambam($USD533.60K) está por debajo de la media de empresas de tamaño similar en el mercado Indian ($USD776.13K).

Compensación vs. Ingresos: La compensación de Kambam ha aumentado más de un 20% en el último año.

CEO

Kambam Reddy (66 yo)

18.4yrs

Permanencia

₹45,048,542

Compensación

Mr. Kambam Nithyananda Reddy has been Vice Chairman of Aurobindo Pharma Limited since June 1, 2012 and serves as a Whole Time Director of Aurobindo Pharma Limited since December 26, 1986 and serves as Mana...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Kambam Reddy	Vice Chairman & MD	18.4yrs	₹45.05m	5.61% ₹ 40.3b
Mettu Madan Reddy	Whole-Time Director	no data	₹60.15m	sin datos
Makkapati Satakarni	President of Biologics	8.8yrs	₹300.00k	sin datos
Santhanam Subramanian	Chief Financial Officer	10.3yrs	₹21.06m	sin datos
S. Kumar	President of Technical	no data	sin datos	sin datos
B. Reddy	Compliance Officer & Company Secretary	8.4yrs	₹4.76m	sin datos
G. Prasad	Senior Vice President of Global Finance & Operations	no data	sin datos	sin datos
Sudhir Singhi	Head of Global Finance Operations	no data	sin datos	sin datos
A. Rama Rao	Chief Quality Officer -Corporate QA	no data	sin datos	0.025% ₹ 176.7m
V. Handa	President of Chemical Research	no data	sin datos	sin datos
Gita Rao	President of RAD-II	no data	₹9.14m	sin datos
Hemant Sharma	President-ARD	no data	₹10.09m	sin datos

9.5yrs

Permanencia media

60yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 524804 es experimentado (9.5 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Kambam Reddy	Vice Chairman & MD	37.9yrs	₹45.05m	5.61% ₹ 40.3b
Mettu Madan Reddy	Whole-Time Director	18.2yrs	₹60.15m	sin datos
Makkapati Satakarni	President of Biologics	less than a year	₹300.00k	sin datos
Penaka Venkata Reddy	Non-Executive Director	37.9yrs	₹600.00k	3.07% ₹ 22.0b
Penaka Sarath Reddy	Non-Executive Director	17.2yrs	₹900.00k	sin datos
Santanu Mukherjee	Independent Director	1.8yrs	₹2.50m	sin datos
Deepali Pant Joshi	Independent Director	no data	₹500.00k	sin datos
Savitha Mahajan	Additional Non-Executive Independent Director	6.9yrs	₹2.20m	sin datos
Venkat Chalasani	Independent Director of Apitoria Pharma Private Limited	1.6yrs	sin datos	sin datos
Mangalam Kumar	Independent Non-Executive Chairman	less than a year	sin datos	sin datos
Girish Vanvari	Non-Executive Independent Director	4yrs	₹2.60m	sin datos

5.5yrs

Permanencia media

64yo

Promedio de edad

Junta con experiencia: La junta directiva de 524804 se considera experimentada (5.5 años de antigüedad promedio).

Aurobindo Pharma Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Aurobindo Pharma Limited, Annual General Meeting, Aug 29, 2024

Aurobindo Pharma Limited Announces Retirement of K. Ragunathan as Chairman of Board of Directors, Effective March 31, 2024

Aurobindo Pharma Limited Appoints N. Ravikiran as Chief Business Officer

Insider recently sold ₹2.1m worth of stock

Less than half of directors are independent

Aurobindo Pharma Limited Approves the Resignation of Dr.(Mrs.) Avnit Bimal Singh as an Independent Director

Recent updates

Second quarter 2025 earnings released: EPS: ₹14.00 (vs ₹12.83 in 2Q 2024)

Aurobindo Pharma Limited to Report Q2, 2025 Results on Nov 09, 2024

Aurobindo Pharma Limited Receives USFDA Approval for Cephalexin Tablets USP, 250 Mg and 500 Mg

Aurobindo Pharma Limited (NSEI:AUROPHARMA) entered into a binding agreement to acquire remaining 49% stake in Gls Pharma Limited from Suresh Pathak and his family members for approximately INR 225 million.

Eugia Steriles Private Limited Receives Its First Product Approval by the United States Food and Drug Administration

Aurobindo Pharma Limited Approves Interim Dividend for the Financial Year 2023-24

Price target increased by 9.8% to ₹1,474

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Aurobindo Pharma Limited, Annual General Meeting, Aug 29, 2024

Aurobindo Pharma Limited (NSEI:AUROPHARMA) announces an Equity Buyback for 5,136,986 shares, representing 0.88% for INR 7,500 million.

Now 20% overvalued after recent price rise

Price target increased by 7.9% to ₹1,292

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Now 21% overvalued after recent price rise

Aurobindo Pharma Limited Announces Retirement of K. Ragunathan as Chairman of Board of Directors, Effective March 31, 2024

Aurobindo Pharma Limited Appoints N. Ravikiran as Chief Business Officer

Insider recently sold ₹2.1m worth of stock

Less than half of directors are independent

Dividend reduced to ₹1.50

Aurobindo Pharma Limited Receives USFDA Approval for Deflazacort Tablets, 6 mg, 18 mg, 30 mg, and 36 mg

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Aurobindo Pharma Limited Approves the Resignation of Dr.(Mrs.) Avnit Bimal Singh as an Independent Director

Price target increased by 7.6% to ₹1,087

Price target increased by 7.5% to ₹1,085

Price target increased by 7.2% to ₹1,071

Insider recently sold ₹9.7m worth of stock

Insider recently sold ₹1.6m worth of stock

New minor risk - Insider selling

Price target increased by 10% to ₹959

Upcoming dividend of ₹3.00 per share at 0.3% yield

Aurobindo Pharma Limited Approves First Interim Dividend, Payable on or Before December 4, 2023

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Associate President of RAD- II recently sold ₹1.6m worth of stock

Aurobindo Pharma Limited Announces Interim Dividend for the Financial Year 2022-23

Price target increased by 15% to ₹775

Aurobindo Pharma Limited Announces Resignation of M. Sivakumaran as Whole-Time Director and Director

Full year 2023 earnings: EPS misses analyst expectations

Aurobindo Pharma Limited to Report Q2, 2024 Results on Nov 14, 2023

Aurobindo Pharma Limited Receives USFDA Approval for Saxagliptin Tablets, 2.5 Mg and 5 Mg

Aurobindo Pharma Limited, Annual General Meeting, Aug 25, 2023

Aurobindo Pharma Limited Announces Completion of US Fda Inspection At Unit III At Bachupally Village, Medchal Malkajgiri District, Telangana

Aurobindo Pharma Limited Announces Classification of US FDA Inspection At Unit XIV, Anakapalli District, Andhra Pradesh

Price target increased by 9.0% to ₹643

Full year 2023 earnings: EPS misses analyst expectations

Insider recently sold ₹1.3m worth of stock

Insider recently bought ₹3.2m worth of stock

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Aurobindo Pharma Limited Approves First Interim Dividend, Payable on or Before March 3, 2023

Aurobindo Pharma Limited Announces Completion Of US FDA Inspection At Unit IX - Reg

Price target decreased to ₹621

Less than half of directors are independent

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Insider recently sold ₹11m worth of stock

Insider recently sold ₹2.7m worth of stock

Aurobindo Pharma Limited (NSEI:AUROPHARMA) completed the acquisition of 34% stake in GLS Pharma Ltd from Suresh and Sunita Pathak.

First quarter 2023 earnings released: EPS: ₹8.88 (vs ₹13.14 in 1Q 2022)

Full year 2022 earnings: EPS and revenues miss analyst expectations

Aurobindo Pharma Limited to Report Q4, 2023 Results on May 30, 2023

Aurobindo Pharma Limited, Annual General Meeting, Aug 02, 2022

Aurobindo Pharma Limited, Annual General Meeting, Aug 02, 2022

Teva Branded Pharmaceutical Products R&D, Inc. and Auspex Pharmaceuticals, Inc. Announces Settlement with Aurobindo to Resolve AUSTEDO® (deutetrabenazine) Patent Dispute

Price target decreased to ₹734

Aurobindo Pharma Limited Announces Fourth Interim Dividend for the Financial Year 2021-22, Payable on or Before June 15, 2022

Full year 2022 earnings: EPS and revenues miss analyst expectations

Now 22% undervalued after recent price drop

Less than half of directors are independent

Aurobindo Pharma Limited (NSEI:AUROPHARMA) agreed to acquire Domestic formulation business of Veritaz Healthcare from Veritaz Healthcare Limited for INR 1710 million.

Aurobindo Pharma Limited (NSEI:AUROPHARMA) agreed to acquire Business and certain assets of Veritaz Healthcare Limited for 1710 million.

Blackstone Reportedly Closing in on Aurobindo's Injectables Business